In Q1 2025, vertical software financing reached $10.4 billion across 552 deals in the US and Canada, with healthcare AI leading the sector in investment activity.

Target Information

The quarter ending Q1 2025 saw significant financing activity in the vertical software sector, with $10.4 billion raised across 552 deals in the United States and Canada. This amount represented 42% of the total capital raised in this space, reflecting strong investor interest, particularly in early-stage companies. The majority of capital was concentrated in the healthcare and AI sectors, with notable rounds around $250 million for Abridge and $30 million for Freed, exemplifying the substantial growth potential of these verticals.

One key player, Abridge, specializes in automating clinical documentation through AI, along with extensive partnership strategies with healthcare systems. With this new funding, Abridge aims to enhance its proprietary technology aimed at improving healthcare communication. Similarly, Freed’s rise in the market showcases the dual paths to success in healthcare AI, with their affordable offerings catering to thousands of clinicians.

Industry Overview

Throughout 2025, the vertical software industry, particularly in the US and Canada, has demonstrated resilience and adaptability amid evolving market conditions. The vertical AI segment is witnessing increased venture capital participation, with h

View Source

Similar Deals

Edwards Lifesciences JenaValve Technology

2026

Other Medical Devices & Implants United States of America
Sofinnova Partners Hemab Therapeutics

2025

Other Bio Therapeutic Drugs United States of America
Knack RCM PPM Partners

2025

Other Healthcare Facilities & Services (NEC) United States of America
LPOXY Therapeutics, Inc. Xeno Biosciences Inc.

2025

Other Bio Therapeutic Drugs United States of America
CitiusTech Inc. Health Data Movers Inc.

2025

Other Healthcare Facilities & Services (NEC) United States of America
Eli Lilly and Company SiteOne Therapeutics, Inc.

2025

Other Proprietary & Advanced Pharmaceuticals United States of America

CCC Intelligent Solutions

invested in

EvolutionIQ

in 2025

in a Other deal

Disclosed details

Transaction Size: $730M

Enterprise Value: $595M

Equity Value: $730M

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert